A Phase I, Open Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic and Clinical Activity of PF-06863135, a BCMA-CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Advanced Multiple Myeloma.
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2017
At a glance
- Drugs PF-06863135 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 08 Nov 2017 Planned End Date changed from 1 Dec 2021 to 6 Dec 2021.
- 08 Nov 2017 Planned primary completion date changed from 1 Mar 2021 to 27 Mar 2021.
- 08 Nov 2017 Planned initiation date changed from 1 Dec 2017 to 6 Dec 2017.